298,660 Shares in Geron Co. (NASDAQ:GERN) Acquired by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new stake in Geron Co. (NASDAQ:GERN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 298,660 shares of the biopharmaceutical company's stock, valued at approximately $1,057,000.

A number of other large investors have also made changes to their positions in the business. Barclays PLC grew its stake in Geron by 114.9% during the 3rd quarter. Barclays PLC now owns 1,299,912 shares of the biopharmaceutical company's stock worth $5,902,000 after buying an additional 694,931 shares during the last quarter. Moody National Bank Trust Division grew its stake in shares of Geron by 76.6% during the fourth quarter. Moody National Bank Trust Division now owns 267,629 shares of the biopharmaceutical company's stock worth $947,000 after acquiring an additional 116,074 shares during the last quarter. Elmwood Wealth Management Inc. acquired a new position in shares of Geron during the fourth quarter valued at about $93,000. Rovin Capital UT ADV raised its position in shares of Geron by 26.9% in the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 3,660 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its position in shares of Geron by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 403,703 shares of the biopharmaceutical company's stock valued at $1,429,000 after purchasing an additional 61,819 shares during the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Price Performance

Shares of Geron stock traded up $0.10 on Monday, hitting $1.28. The company's stock had a trading volume of 3,054,019 shares, compared to its average volume of 11,533,824. The company has a market capitalization of $812.07 million, a price-to-earnings ratio of -4.02 and a beta of 0.76. The firm has a fifty day moving average price of $1.49 and a 200-day moving average price of $2.72. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron Co. has a 1 year low of $1.17 and a 1 year high of $5.34.

Geron (NASDAQ:GERN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $39.60 million during the quarter, compared to the consensus estimate of $49.88 million. During the same period in the prior year, the company posted ($0.07) EPS. The business's quarterly revenue was up 12927.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Geron Co. will post -0.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on GERN shares. B. Riley cut shares of Geron from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and issued a $5.00 target price on shares of Geron in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a research report on Wednesday, March 12th. Stifel Nicolaus cut their price objective on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Finally, Barclays restated an "overweight" rating and issued a $4.00 price objective (down from $9.00) on shares of Geron in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $5.06.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.